Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment.

Arendt M, Munk-Jørgensen P, Sher L, Jensen SO.

Drug Alcohol Depend. 2011 Apr 1;114(2-3):134-9. doi: 10.1016/j.drugalcdep.2010.09.013. Epub 2010 Oct 25.

PMID:
20971585
2.

Mortality following treatment for cannabis use disorders: predictors and causes.

Arendt M, Munk-Jørgensen P, Sher L, Jensen SO.

J Subst Abuse Treat. 2013 Apr;44(4):400-6. doi: 10.1016/j.jsat.2012.09.007. Epub 2012 Nov 2.

PMID:
23122774
3.

Drug-related decrease in neuropsychological functions of abstinent drug users.

van Holst RJ, Schilt T.

Curr Drug Abuse Rev. 2011 Mar;4(1):42-56. Review.

PMID:
21466500
4.

Psychopathology among cannabis-dependent treatment seekers and association with later substance abuse treatment.

Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jørgensen P.

J Subst Abuse Treat. 2007 Mar;32(2):113-9. Epub 2006 Oct 27.

PMID:
17306720
6.

All-cause mortality among individuals with disorders related to the use of methamphetamine: a comparative cohort study.

Callaghan RC, Cunningham JK, Verdichevski M, Sykes J, Jaffer SR, Kish SJ.

Drug Alcohol Depend. 2012 Oct 1;125(3):290-4. doi: 10.1016/j.drugalcdep.2012.03.004. Epub 2012 Apr 13.

PMID:
22503689
7.

Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia.

Arendt M, Mortensen PB, Rosenberg R, Pedersen CB, Waltoft BL.

Arch Gen Psychiatry. 2008 Nov;65(11):1269-74. doi: 10.1001/archpsyc.65.11.1269.

PMID:
18981338
8.

Self-reported drug use and mortality among a nationwide sample of Swedish conscripts - a 35-year follow-up.

Davstad I, Allebeck P, Leifman A, Stenbacka M, Romelsjö A.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):383-90. doi: 10.1016/j.drugalcdep.2011.04.025. Epub 2011 Jun 12.

PMID:
21664771
9.

[Sociodemographic profiles, addictive and mental comorbidity in cannabis users in an outpatient specific setting].

Guillem E, Pelissolo A, Vorspan F, Bouchez-Arbabzadeh S, Lépine JP.

Encephale. 2009 Jun;35(3):226-33. doi: 10.1016/j.encep.2008.03.010. Epub 2008 Aug 19. French.

PMID:
19540408
10.

Major depression: the relative contribution of gender, MDMA, and cannabis use.

Durdle H, Lundahl LH, Johanson CE, Tancer M.

Depress Anxiety. 2008;25(3):241-7.

PMID:
17345601
11.

[Assessment of disorders after chronic psychoactive drug abuse in patients hospitalized in detoxification units].

Chrostek Maj J, Kroch S, Kamenczak A, Polewka A, Szerszeń-Motyka J.

Przegl Lek. 2004;61(4):317-9. Polish.

PMID:
15521592
12.

Heavy cannabis users seeking treatment- prevalence of psychiatric disorders.

Arendt M, Munk-Jørgensen P.

Soc Psychiatry Psychiatr Epidemiol. 2004 Feb;39(2):97-105.

PMID:
15052390
13.

Does accumulating exposure to illicit drugs bring forward the age at onset in schizophrenia?

Power BD, Dragovic M, Jablensky A, Stefanis NC.

Aust N Z J Psychiatry. 2013 Jan;47(1):51-8. doi: 10.1177/0004867412461957. Epub 2012 Oct 5.

PMID:
23042939
14.

Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases.

Licht CL, Christoffersen M, Okholm M, Damgaard L, Fink-Jensen A, Knudsen GM, Erritzoe D.

Hum Psychopharmacol. 2012 Jul;27(4):352-63. doi: 10.1002/hup.2234. Epub 2012 Jun 14.

PMID:
22696164
15.

Pathways into ecstasy use: the role of prior cannabis use and ecstasy availability.

Zimmermann P, Wittchen HU, Waszak F, Nocon A, Höfler M, Lieb R.

Drug Alcohol Depend. 2005 Sep 1;79(3):331-41.

PMID:
15913921
16.

MDMA: interactions with other psychoactive drugs.

Mohamed WM, Ben Hamida S, Cassel JC, de Vasconcelos AP, Jones BC.

Pharmacol Biochem Behav. 2011 Oct;99(4):759-74. doi: 10.1016/j.pbb.2011.06.032. Epub 2011 Jul 5. Review.

PMID:
21756931
17.

Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users.

Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A.

J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):93-9. doi: 10.1097/QAI.0b013e3181900129.

PMID:
19295339
18.

5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study.

Martín-Santos R, Torrens M, Poudevida S, Langohr K, Cuyás E, Pacifici R, Farré M, Pichini S, de la Torre R.

Addict Biol. 2010 Jan;15(1):15-22. doi: 10.1111/j.1369-1600.2009.00180.x.

PMID:
19878141
19.

Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.

Christiansen P, Bjerre K, Ejlertsen B, Jensen MB, Rasmussen BB, Lænkholm AV, Kroman N, Ewertz M, Offersen B, Toftdahl DB, Møller S, Mouridsen HT; Danish Breast Cancer Cooperative Group..

J Natl Cancer Inst. 2011 Sep 21;103(18):1363-72. doi: 10.1093/jnci/djr299. Epub 2011 Aug 31.

PMID:
21881042
20.

Predictors of mortality among injecting and non-injecting HIV-negative drug users in northern Thailand.

Quan VM, Vongchak T, Jittiwutikarn J, Kawichai S, Srirak N, Wiboonnatakul K, Razak MH, Suriyanon V, Celentano DD.

Addiction. 2007 Mar;102(3):441-6.

PMID:
17298652

Supplemental Content

Support Center